Overview

Clinical Study of Epoetin Beta to Chemotherapy-Induced Anemia (CIA) Patients

Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
This is a study to investigate the clinical efficacy and safety of epoetin beta 36,000 IU compared with placebo when administrated subcutaneously (s.c.) once-weekly for 12 weeks to anemic patients with lung cancer or gynecologic cancer undergoing chemotherapy.
Phase:
Phase 3
Details
Lead Sponsor:
Chugai Pharmaceutical
Treatments:
Epoetin Alfa